Friulchem SpA
MIL:FCM

Watchlist Manager
Friulchem SpA Logo
Friulchem SpA
MIL:FCM
Watchlist
Price: 0.81 EUR 2.53% Market Closed
Market Cap: 6.5m EUR

Relative Value

There is not enough data to reliably calculate the relative value of FCM.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

FCM Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
71
vs Industry
89
Median 3Y
0.3
Median 5Y
0.3
Industry
2.6
Forward
0.2
vs History
vs Industry
1
Median 3Y
-26.8
Median 5Y
-26.8
Industry
21.4
Forward
-80.2
vs History
50
vs Industry
53
Median 3Y
0.5
Median 5Y
0.5
Industry
16.4
vs History
vs Industry
Median 3Y
-6.8
Median 5Y
-3.2
Industry
22.8
vs History
80
vs Industry
70
Median 3Y
0.7
Median 5Y
0.8
Industry
2.2
vs History
17
vs Industry
84
Median 3Y
0.5
Median 5Y
0.5
Industry
2.9
Forward
0.4
vs History
31
vs Industry
63
Median 3Y
2.5
Median 5Y
2.5
Industry
5.5
vs History
17
vs Industry
37
Median 3Y
7.8
Median 5Y
7.7
Industry
13
Forward
7.5
vs History
31
vs Industry
25
Median 3Y
17.4
Median 5Y
17.4
Industry
16.5
Forward
19.3
vs History
50
vs Industry
54
Median 3Y
1
Median 5Y
1
Industry
15.6
vs History
vs Industry
Median 3Y
-10
Median 5Y
-10.3
Industry
18.7
vs History
17
vs Industry
73
Median 3Y
0.5
Median 5Y
0.5
Industry
1.9

Multiples Across Competitors

FCM Competitors Multiples
Friulchem SpA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IT
Friulchem SpA
MIL:FCM
6.5m EUR 0.3 -26.8 8.1 17.4
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.5 37.2 39.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.9B USD 5.4 19.9 16.2 21.1
CH
Roche Holding AG
SIX:ROG
261.4B CHF 4.2 27.7 11.8 13.8
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.9 30.2 108.4 158.6
CH
Novartis AG
SIX:NOVN
210.3B CHF 4.7 18.4 11.7 15.1
US
Merck & Co Inc
NYSE:MRK
264.8B USD 4.1 13.9 9.9 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.6 14.1 9.9 11.5
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.2B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
IT
Friulchem SpA
MIL:FCM
Average P/E: 24.3
Negative Multiple: -26.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.2
37%
0.8
CH
Novartis AG
SIX:NOVN
18.4
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.1
3%
4.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IT
Friulchem SpA
MIL:FCM
Average EV/EBITDA: 400.5
8.1
26%
0.3
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.8
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.7
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
1%
9.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IT
Friulchem SpA
MIL:FCM
Average EV/EBIT: 1 713.7
17.4
48%
0.4
US
Eli Lilly and Co
NYSE:LLY
39.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.8
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.6
23%
6.9
CH
Novartis AG
SIX:NOVN
15.1
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5